$OPK News

OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides

Is OPKO Health (OPK) Pricing In Too Much For Sales?

Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

Opko Health stock soars on $722M BioReference asset sale

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue

Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

OPKO Health: A Hold As Progress Continues

OPKO Health (OPK) Is Up 36.0% After Narrower Q2 Loss And New 2026 Guidance Has The Bull Case Changed?

OPKO Health, Inc. Q2 2026 Earnings Call Summary

OPKO Health Q2 Earnings Call Highlights